Novo Says US Approves Weekly Insulin for Children Aged 10 and Older
Key Facts
Novo Nordisk said on October 23, 2026, that the US Food and Drug Administration had approved the use of Awiqli in children aged 10 and older with type 2 diabetes. The company said the product, at a concentration of 700 units/mL, is used alongside diet and exercise to improve blood sugar control. Novo described the drug as the first long-acting basal insulin administered once weekly for this age group. According to the company, the basal dosing schedule cuts injections from 7 a week to one. But the US agency materials reviewed for this report still list the use for adults, and did not show anything confirming the expansion to children.
The announcement could mark a significant expansion of basal insulin use in children, but the claim remains attributed to Novo until an updated agency record or label appears. The company says fewer injections could make the treatment routine more manageable for some patients. Its statement quoted Michael Rady, executive medical director, as saying the weekly schedule could make the basal insulin routine "more manageable." The change concerns injection frequency, and the announcement does not provide evidence that the schedule alone improves clinical outcomes. The agency initially recorded US approval of Awiqli on March 26, 2026, to improve blood sugar control in adults with type 2 diabetes.
The discrepancy between the company's announcement and the available regulatory information reflects the dates of the materials reviewed. The drug label published through the US National Library of Medicine, amended in March 2026, says Awiqli's safety and efficacy have not been established in children and specifies the indication for adults with type 2 diabetes. The agency's new-drug approvals page also records March 26, 2026, as the date of initial approval, and refers to treatment for adults. This means the October 23 announcement adds a claim of an age-group expansion, while those materials do not yet reflect that update. The final regulatory picture therefore depends on publication of an updated label or approval record specifying use in children.
Novo linked the announcement to the burden of type 2 diabetes among young people, citing a model-based estimate that the number of people aged 19 or younger with the disease could approach 84,000 by 2050. This is a future projection cited by the company, not a count of current cases. The company said care includes healthy nutrition, physical activity, family support and diabetes education. This context places the treatment within broader care beyond insulin use alone. The announcement, in the material available, did not report results from a clinical trial in children or figures on the expected degree of improvement in blood sugar control.
In the market, Novo Nordisk shares, listed under ticker NVO, closed at $39.43 on October 22, compared with a close of $39.06 on October 21, according to EL7 data. Closing data alone do not establish that the move was linked to the approval announcement, which came the day after the October 22 close. The data provided did not include a post-announcement price or a benchmark comparison that would allow its impact on the shares to be isolated. The key development for investors remains whether US regulatory materials will reflect the expansion announced by the company. Novo's announcement did not specify when an additional update to the label or regulatory record would be published.